As prostate cancer is considered a heterogenous disease, for which only a few cell lines are available of which a subset is AR-driven, we next tested whether drug resistance as a result of TLE3 loss could be confirmed in two other prostate cancer cell lines; CWR-R1 and LAPC4. The gene discussed is AR; the disease is prostate cancer.